Nectar Lifesciences Ltd.
NSE: NECLIFE · Pharmaceuticals · sector
₹10.46NSE close 2026-10-26
Key numbers
Market cap₹203 cr
Price₹10.46
52w high / low₹22 / ₹9
P/E–Sector median 27.9x
P/B0.3xSector median 2.9x
Book value₹30.0
Dividend yield–Sector median 0.48%
ROE-31.9%Sector median 11.7%
ROCE1.9%Sector median 12.3%
OPM-20.8%Sector median 14.0%
Debt / equity0.00xSector median 0.16x
EV/EBITDA–Sector median 18.6x
Interest cover0.3x
Current ratio9.71x
Sales growth 3y–Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹125 cr vs borrowings ₹0 cr (FY26): cash is higher (net cash).
- Borrowings fell in each of the last 3 years (₹754 cr → ₹0 cr).
- Operating profit covered interest 0.3x in the last 12 months.
- No promoter shares are pledged.
- Promoter holding rose by 6.93 percentage points in a year, to 51.84% (2026-09-30).
- Operating cash flow was below net profit in 1 of the last 5 years (FY26).
- Net loss in 5 of the last 8 quarters.
- Revenue was higher than a year earlier in 0 of the last 4 quarters.
- No dividend in the last 5 financial years.
- Price ₹10.46 on 2026-10-26: -53.3% from the 52-week high, +12.5% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹42.66 · low ₹9.76
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 428 | 455 | 431 | 281 | 5 | 0 | 0 | 0 |
| EBITDA | 43 | 45 | -154 | -62 | -1 | 86 | -59 | -28 |
| OPM % | 10.1% | 9.8% | -35.8% | -22.1% | -20.8% | – | – | -2,77,000.0% |
| Other income | 1 | 1 | 0 | 0 | 1 | 1 | 8 | 3 |
| Net profit | 6 | 8 | -130 | -63 | -176 | 14 | -68 | -15 |
| EPS (₹) | 0.25 | 0.35 | -5.80 | -2.82 | -7.84 | 0.64 | -3.38 | -0.79 |
| Revenue YoY | -98.8% | -100.0% | -100.0% | -100.0% | ||||
| Profit YoY | -3,243.0% | +82.0% | – | – |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 1,669 | 1,525 | 1,686 | 1,673 | 0 | 5 |
| EBITDA | 159 | 54 | 153 | -26 | -61 | -1 |
| Net profit | 25 | -24 | 5 | -114 | -293 | -245 |
| EPS (₹) | 1.12 | -1.08 | 0.22 | -5.07 | -13.40 | -11.37 |
| Revenue growth | -8.6% | +10.6% | -0.7% | -100.0% | -99.7% | |
| Profit growth | -196.5% | – | -2,378.2% | – | – | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | – | – | -99.7% |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | -44.4% (2y) | -17.9% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 1,065 | 1,069 | 956 | 582 |
| Borrowings | – | 754 | 636 | 582 | 0 |
| Cash & equivalents | – | 18 | 20 | 20 | 125 |
| Total assets | – | 2,189 | 2,191 | 2,047 | 622 |
| Fixed assets | – | 613 | 590 | 577 | 103 |
| Capital work in progress | – | 78 | 66 | 57 | 0 |
| Investments | – | 0 | 0 | 0 | 0 |
| Receivables | – | 280 | 379 | 345 | 0 |
| Inventory | – | 673 | 709 | 690 | 0 |
| Payables | – | 319 | 420 | 438 | 0 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 95 | 134 | 225 | 169 | -349 |
| Cash from investing | 17 | 52 | -17 | -42 | 1,208 |
| Cash from financing | -119 | -186 | -205 | -128 | -767 |
| Capex | 25 | 30 | 29 | 44 | 12 |
| Free cash flow | 70 | 104 | 195 | 126 | -361 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | -2.3% | 0.5% | -11.9% | -50.3% |
| ROCE % | – | 2.0% | 6.2% | -5.7% | -8.9% |
| Debtor days | – | 67 | 82 | 75 | – |
| Inventory days | – | 212 | 215 | 184 | – |
| Payable days | – | 100 | 127 | 117 | – |
| Cash conversion cycle (days) | – | 179 | 170 | 142 | – |
| Working capital days | – | 81 | 67 | 47 | – |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 51.84% |
| FIIs | 0.50% |
| DIIs | 3.90% |
| Government | 0.02% |
| Public (non-institutions) | 43.74% |
| Quarter | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Jan 2026 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 44.53% | 44.53% | 44.91% | 44.91% | 51.84% | 51.84% | 51.84% | 51.84% |
| Promoter group | % |
|---|---|
| Sanjiv Goyal | 24.63% |
| Sanjiv (HUF) - Karta Sanjiv Goyal | 22.46% |
| Raman Goyal | 4.76% |
| Nectar Organics Private Limited | 0.00% |
| Orient Alloys Private Limited | 0.00% |
| Public holders above 1% | % |
|---|---|
| Rajasthan Global Securities Private Limited | 3.90% |
72,334 shareholders. Pledged: 0.00% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| NECLIFE | ₹203 cr | – | 0.3x | -31.9% | 1.9% | -20.8% | – | – |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2025-12-24 | Buyback | Buy Back |
| 2024-09-13 | Other | Annual General Meeting |
| 2023-09-14 | Other | Annual General Meeting |
| 2022-09-13 | Other | Annual General Meeting |
| 2021-09-13 | Other | Annual General Meeting |
| 2020-09-11 | Dividend | Annual General Meeting/Dividend - Rs 0.05 Per Share |
| 2019-09-19 | Dividend | Annual General Meeting/Dividend - Rs 0.05 Per Share |
| 2018-09-19 | Dividend | Annual General Meeting/Dividend- Re 0.05 Per Share |
| 2017-09-20 | Dividend | Annual General Meeting/Dividend - Re 0.05 Per Share |
| 2016-09-22 | Dividend | Annual General Meeting/Dividend - Re 0.10 Per Share |
| 2015-09-22 | Dividend | Annual General Meeting/ Dividend - Re 0.10/- Per Share |
| 2014-08-21 | Dividend | Annual General Meeting / Final Dividend - Re 0.10/- Per Share |
| 2013-09-19 | Dividend | Annual General Meeting And Dividend Re.0.10 Per Share |
| 2012-09-20 | Dividend | Annual General Meeting And Dividend Re.0.10 Per Share |
| 2011-09-21 | Dividend | Annual General Meeting And Dividend Re.0.10 Per Share |
| 2010-09-23 | Other | Annual General Meeting |
| 2010-01-21 | Other | Int Div-Re.0.25 Per Sharepurpose Revised |
| 2009-09-03 | Other | Agm/Div-Re.0.10 Per Share |
| 2008-11-12 | Split | Fv Split Rs.10/- To Re.1/ |
| 2008-09-18 | Dividend | Agm/Dividend - 40% |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | NECLIFE |
| BSE code | 532649 |
| ISIN | INE023H01027 |
| Face value | ₹1.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.